Balaxi Pharmaceuticals Limited
NSE:BALAXI.NS
88.32 (INR) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,386.479 | 3,364.326 | 2,793.878 | 2,313.331 | 456.324 | 135.954 | -0.001 | -6.145 | 0.475 | 1.237 | 1.929 | 0.861 |
| Cost of Revenue
| 1,324.553 | 2,024.156 | 1,955.963 | 1,721.479 | 335.767 | 104.699 | 0.019 | 0.924 | 0.841 | 0.014 | 0 | 0 |
| Gross Profit
| 1,061.926 | 1,340.17 | 837.915 | 591.852 | 120.557 | 31.255 | -0.02 | -7.069 | -0.366 | 1.224 | 1.929 | 0.861 |
| Gross Profit Ratio
| 0.445 | 0.398 | 0.3 | 0.256 | 0.264 | 0.23 | 39.8 | 1.15 | -0.771 | 0.989 | 1 | 1 |
| Reseach & Development Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0.015 | -0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 385.087 | 485.252 | 131.409 | 5.791 | 1.238 | 1.343 | 2.208 | 0.035 | 0.153 | 0.081 | 0.093 | 0 |
| Selling & Marketing Expenses
| 6.552 | 8.407 | 10.214 | 1.018 | 1.018 | 0.154 | 0.253 | 0.042 | 0.034 | 0.073 | 0.008 | 0 |
| SG&A
| 385.087 | 485.252 | 141.623 | 6.809 | 2.256 | 1.497 | 2.461 | 0.077 | 0.188 | 0.154 | 0.101 | 0.084 |
| Other Expenses
| -658.839 | 26.369 | 193.18 | 160.871 | 22.509 | 8.088 | 4.932 | 1.033 | 0.999 | 0.421 | 0 | 0 |
| Operating Expenses
| 658.839 | 792.316 | 334.803 | 167.68 | 59.454 | 14.939 | 7.393 | 1.11 | 1.186 | 0.804 | 0.339 | 0.252 |
| Operating Income
| 403.087 | 574.223 | 546.639 | 443.848 | 82.335 | 16.316 | -7.679 | -7.896 | -0.695 | 1.608 | 1.59 | 0.609 |
| Operating Income Ratio
| 0.169 | 0.171 | 0.196 | 0.192 | 0.18 | 0.12 | 15,357 | 1.285 | -1.462 | 1.3 | 0.824 | 0.708 |
| Total Other Income Expenses Net
| -382.933 | -5 | -1.416 | -0.555 | 5.605 | 8.078 | -0.02 | 15.2 | -0.468 | -0.137 | -0.1 | -0.024 |
| Income Before Tax
| 20.154 | 569.223 | 545.223 | 443.293 | 88.737 | 24.394 | -7.699 | -7.896 | -1.163 | 1.471 | 1.489 | 0.585 |
| Income Before Tax Ratio
| 0.008 | 0.169 | 0.195 | 0.192 | 0.194 | 0.179 | 15,397 | 1.285 | -2.448 | 1.189 | 0.772 | 0.679 |
| Income Tax Expense
| 44.023 | 109.598 | 68.645 | 61.919 | 27.698 | 4.734 | 0.02 | 0.249 | -0.359 | 0.448 | 0.394 | 0.143 |
| Net Income
| -23.869 | 459.625 | 476.578 | 381.373 | 61.036 | 19.659 | -7.719 | -7.896 | -0.804 | 1.024 | 1.095 | 0.442 |
| Net Income Ratio
| -0.01 | 0.137 | 0.171 | 0.165 | 0.134 | 0.145 | 15,438 | 1.285 | -1.692 | 0.827 | 0.568 | 0.513 |
| EPS
| -0.46 | 9.16 | 9.53 | 7.63 | 1.62 | 1.29 | -0.51 | -0.11 | -0.053 | 0.1 | 0.31 | 0.63 |
| EPS Diluted
| -0.46 | 9.08 | 9.53 | 7.63 | 1.62 | 1.29 | -0.51 | -0.11 | -0.053 | 0.1 | 0.31 | 0.63 |
| EBITDA
| 424.071 | 591.748 | 551.761 | 446.826 | 88.812 | 24.439 | -7.659 | -7.221 | -0.673 | 1.625 | 1.593 | 0.615 |
| EBITDA Ratio
| 0.178 | 0.176 | 0.197 | 0.193 | 0.195 | 0.18 | 15,317 | 1.175 | -1.417 | 1.313 | 0.826 | 0.714 |